Table 3.
Case-control data set patient medication exposures
| Medication Name | No AKI (n = 357) (%) | AKI (n = 357) (%) | pRIFLE R (n = 291) (%) | pRIFLE I (n = 65) (%) | pRIFLE F (n = 1) (%) |
|---|---|---|---|---|---|
| Abelcet | 0 (0) | 4 (1.1)a | 2 (0.6) | 2 (3.3) | 0 (0) |
| Acyclovir | 21 (5.9) | 22 (6.2) | 16 (5.5) | 6 (9.2) | 0 (0) |
| Amikacin | 4 (1.1) | 4 (1.1) | 4 (1.4) | 0 (0) | 0 (0) |
| Amphotericin | 1 (0.2) | 9 (2.5)a | 7 (2.4)a | 2 (3.3) | 0 (0) |
| Captopril | 4 (1.1) | 3 (0.8) | 3 (1.0) | 0 (0) | 0 (0) |
| Carboplatin | 10 (2.8) | 5 (1.4) | 5 (1.7) | 0 (0) | 0 (0) |
| Cefotaxime | 28 (7.8) | 47 (13.2) | 31 (1.1) | 16 (24.6) | 0 (0) |
| Ceftazidime | 80 (22.4) | 87 (24) | 65 (22) | 22 (33.8)a | 0 (0) |
| Cefuroxime | 6 (1.7) | 4 (1.1) | 4 (1.4) | 0 (0) | 0 (0) |
| Cidofovir | 3 (0.8) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Cisplatin | 12 (3.4) | 24 (6.7)a | 18 (6.2) | 6 (9.2)a | 0 (0) |
| Colistimethate | 6 (1.7) | 10 (2.8) | 9 (3.1) | 1 (1.5) | 0 (0) |
| Cyclosporine | 4 (1.1) | 4 (1.1) | 4 (1.4) | 0 (0) | 0 (0) |
| Dapsone | 3 (0.8) | 4 (1.1) | 3 (1.0) | 1 (1.5) | 0 (0) |
| Enalapril | 11 (3) | 10 (2.8) | 8 (2.7) | 2 (3.3) | 0 (0) |
| Foscarnet | 1 (0.2) | 2 (0.5) | 2 (0.6) | 0 (0) | 0 (0) |
| Ganciclovir | 2 (0.5) | 4 (1.1) | 3 (1.0) | 1 (1.5) | 0 (0) |
| Gentamicin | 78 (21.8) | 97 (27.1) | 73 (25.1) | 24 (36.9)a | 0 (0) |
| Ibuprofen | 35 (9.8) | 39 (10.9) | 28 (9.6) | 11 (16.9) | 0 (0) |
| Ifosfamide | 15 (4.2) | 5 (1.4) | 5 (1.7) | 0 (0) | 0 (0) |
| Ketorolac | 19 (5.3) | 18 (5.0) | 12 (4.1) | 5 (7.7) | 1 (100) |
| Mesalamine | 3 (0.8) | 2 (0.5) | 2 (0.6) | 0 (0) | 0 (0) |
| Methotrexate | 27 (7.6) | 27 (7.6) | 20 (6.9) | 7 (10.7) | 0 (0) |
| Nafcillin | 3 (0.8) | 6 (1.7) | 6 (2.0) | 0 (0) | 0 (0) |
| Naproxen | 2 (0.5) | 3 (0.8) | 3 (1.0) | 0 (0) | 0 (0) |
| Piperacillin/piperacillin and tazobactam | 38 (10.6) | 60 (16.8)a | 43 (14.8) | 17 (26.2)a | 0 (0) |
| Sirolimus | 1 (0.2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Sulfasalazine | 0 (0) | 1 (0.2) | 1 (0.3) | 0 (0) | 0 (0) |
| Tacrolimus | 19 (5.3) | 19 (5.3) | 15 (5.2) | 4 (6.2) | 0 (0) |
| Ticarcillin/clavulanic acid | 49 (13.7) | 47 (13.2) | 38 (13.1) | 9 (13.8) | 0 (0) |
| Tobramycin | 16 (4.5) | 18 (5.0) | 16 (5.5) | 2 (3.1) | 0 (0) |
| Trimethoprim/Sulfamethoxazole | 111 (31.1) | 132 (36.9) | 103 (35.4) | 29 (44.6) | 0 (0) |
| Valganciclovir | 6 (1.7) | 10 (2.8) | 7 (2.4) | 3 (4.6) | 0 (0) |
| Vancomycin | 92 (25.8) | 131 (36.7)a | 98 (33.6)a | 33 (50.8)a | 0 (0) |
a
P < 0.05 compared to patients with no AKI.